Recent presentations
In 2024, Dr. Travis presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago:
Long-term Survivorship in Testicular Cancer.
In June 2022, we presented six abstracts at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago:
Nakshatri S, Shuey M, Shahbazi M, Trendowski M, Dinh P, Feldman D, Hamilton R, Vaughn D, Fung C, Kollmansberger C, Einhorn L, Frisina R, Travis LB, Dolan E, Cox N. Building a model to predict the risk of multiple severe neurotoxicities in cancer survivors after cisplatin treatment. Presented at ASCO 2022 Annual Meeting, Chicago, IL. J Clin Oncol 40, 2022 (suppl 16, abstr e24066. DOI: 10.1200/JCO.2022.40.16_suppl.e24066
Dinh P, Monahan P, Clasen S, Sesso H, Einhorn L, Fossa S, Vaughn D, Martin N, Fung C, Travis LB. Impact of Adverse Health Outcomes on Self-Reported Physical and Mental Health in U.S. Testicular Cancer Survivors. Presented at ASCO 2022 Annual Meeting, Chicago, IL. J Clin Oncol 40, 2022 (suppl 16; abstr 12080. DOI: 10.1200/JCO.2022.40.16_suppl. 12080
Sanchez V, Shuey M, Dinh P, Monahan P, Sesso H, Dolan E, Einhorn L, Vaughn D, Martin N, Fung C, Frisina R, Travis LB. Impact of Cisplatin-induced Hearing Loss on Patient-Reported Social and Emotional Functioning. Presented at ASCO 2022 Annual Meeting, Chicago IL. J Clin Oncol 40, 2022 (suppl 16; abstr 12120). DOI: 10.1200/JCO.2022.40.16_suppl. 12120
Shuey M, Sanchez V, Dinh P, Monahan P, Sesso H, Dolan E, Einhorn L, Vaughn D, Martin N, Fung C, Frisina R, Travis LB. Cisplatin-induced Tinnitus and Patient-Reported Outcomes in Adult-Onset Cancer Survivors. Presented at ASCO 2022 Annual Meeting, Chicago, IL. J Clin Oncol 40, 2022 (suppl 16; abstr e24089). DOI: 10.1200/JCO.2022.40.16_suppl.e24089
Zheng Y, Wang J, Dinh P, Nathanson K, Weathers B, Jacobs L, Vaughn D, Hou L, Travis LB. Epigenetic Age Acceleration in U.S. Testicular Cancer Survivors. Presented at ASCO 2022 Annual Meeting, Chicago, IL. J Clin Oncol 40, 2022. Suppl 16; abstr 5033 DOI: 10.1200/JCO.2022.40.16_suppl. 5033
Miller M, Ashkar R, Althouse S, Hanna N, Abonour R, Travis LB, Einhorn L, Adra N, Abu Zaid M. Adverse health outcomes in testis cancer survivors following high dose chemotherapy and autologous stem cell transplant. Presented at ASCO 2022 Annual Meeting, Chicago, IL. J Clin Oncol 40, 2022 (suppl 16; abstr 12083). DOI: 10.1200/JCO.2022.40.16_suppl. 12083
The initial phases of the study revealed results that investigators are now examining more closely, including:
